Abstract
During the last decade, resulting from expanded knowledge in tumor biology, several new and target-specific approaches have been presented. With some exceptions, however, most early clinical trials with these compounds are discouraging, suggesting that the expanding knowledge might not easily translate into new substantially better anti-cancer drugs. One of the classical chemotherapeutic agents is melphalan, first synthesized over fifty years ago. The anti-tumor effect has been attributed to alkylation of cellular nucleophiles, among them DNA. Intravenous melphalan has single-agent activity in a variety of solid tumors and has good activity alone or combined with other drugs or radiation in high-dose bone marrow transplant regimens for breast cancer, ovarian cancer, testicular cancer and multiple myeloma. Recent studies suggest a continuous role for melphalan as part of high dose combination therapy in advanced solid tumor malignancies. Immediately after the first publication on melphalan (p-L-bis(2-chloroethyl)aminophenylalanine), investigators began attempting to improve the therapeutic index and thus provide a greater margin of clinical safety during treatment with the drug. The amino-acid based chemical structure of melphalan invites to modification of both the N- and C-termini as well as incorporation into peptides. In this review we discuss the past and present history of melphalan in the perspective of modern cancer chemotherapy, from the medicinal chemists point of view, and with special emphasis on how target-directed approaches have been applied to the molecule.
Keywords: Melphalan, Prodrugs, Chemotherapeutics, Cancer target
7